Alzheimer's disease (AD) is the most prevalent neurodegenerative disease in ageing,
affecting around 46 million people worldwide but few treatments are currently available. The …

Polymorphism in the apolipoprotein E (APOE) gene is a major genetic risk determinant of
late-onset Alzheimer disease (AD), with the APOE* ε 4 allele conferring an increased risk …

Alzheimer disease (AD) is characterized by wide heterogeneity in cognitive and behavioural
syndromes, risk factors and pathophysiological mechanisms. Addressing this phenotypic …

Introduction We estimated the age-specific duration of the preclinical, prodromal, and
dementia stages of Alzheimer's disease (AD) and the influence of sex, setting …

Importance The Anti-Amyloid Treatment in Asymptomatic Alzheimer disease (A4) Study is an
ongoing prevention trial in clinically normal older individuals with evidence of elevated brain …

Importance Mounting evidence suggests that sex differences exist in the pathologic
trajectory of Alzheimer disease. Previous literature shows elevated levels of cerebrospinal …

After advanced age, female sex is the major risk factor for late-onset Alzheimer's disease
(AD), the most common cause of dementia affecting over 24 million people worldwide. The …

Alzheimer's disease (AD) is the most common form of dementia and may contribute to 60–
70% of cases. Worldwide, around 50 million people suffer from dementia and the prediction …

Large phenotypically diverse research cohorts with both amyloid and tau PET have only
recently come into existence. Our objective was to determine relationships between the …

Studies have shown that women on the Alzheimer's disease (AD) continuum have more
pathological tau in the brain and cerebrospinal fluid (CSF), than men. Some studies have …